PF-Atlas › Clinical Trials › NCT03796364

Clinical Study of Endostatin in Improving Radiation Pneumonia and Fibrosis

Endostar · Phase 2

Registry ID

NCT03796364

Phase

Phase 2

Status

Completed

Drug / intervention

Endostar

Sponsor

Xinqiao Hospital of Chongqing

Start

2018-09-01

Enrollment

126

Locations

About this trial

To verify the efficacy and safety of endostatin in the treatment of SRILI（symptomatic radiation-induced lung injury） and fibrosis. The results of this study are expected to be a new clinical strategy for the treatment of radiation pneumonia and fibrosis.

View NCT03796364 on ClinicalTrials.gov →

Explore related

All Endostar trials All IPF trials

Medical disclaimer. This page summarizes public trial data for NCT03796364 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.